The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Is There a Role for Pelvic Irradiation in Localized Prostate Adenocarcinoma? Preliminary Results of GETUG-01
Open accessAbstract
Purpose: To assess the benefit and toxicity and quality-of-life (QOL) outcomes of pelvic nodes irradiation in nonmetastatic prostate carcinoma patients. Patients and Methods: Between December 1998 and June 2004, 444 patients with T1b-T3, N0 pNx, M0 prostate carcinoma were randomly assigned to either pelvic and prostate radiotherapy or prostate radiotherapy only. Patients were stratified according to the prognostic factor of lymph node involvement (LNI). Short-term 6-month neoadjuvant and concomitant hormonal therapy was allowed only for patients in the high-risk group. The pelvic dose was 46 Gy. The total dose recommended to the prostate was changed during the course of the study from 66 Gy to 70 Gy. Criteria for progression-free survival (PFS) included biologic prostate-specific antigen recurrences or a local or metastatic evolution. Acute and late toxicities were recorded according to the Radiation Therapy Oncology Group and Late Effects in Normal Tissues Subjective, Objective, Management, and Analytic scales, respectively. The QOL outcome was recorded with the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire C30, the International Prostatic Symptom Score, and the Sexual Function Index scales. Results: With a 42.1-month median follow-up time, the 5-year PFS and overall survival were similar in the two treatment arms for the whole series and for each stratified group. On multivariate analysis, low LNI risk and hormonal therapy were statistically associated with increased PFS. However, subgroup analyses based on these factors did not show any benefit for pelvic irradiation. There were no significant differences in acute and late digestive toxicities and in QOL outcomes. Conclusion: Pelvic node irradiation was well tolerated but did not improve PFS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Regression Models and Life-Tables
Cox, D. R. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_37 · Cited by 26,297
Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., Filiberti, A., Flechtner, H., Fleishman, S. B., Haes, J. C. J. M. D., et al. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.5.365 · Cited by 16,005
Peto, R., Pike, M. C., Armitage, P., Breslow, N. E., Cox, D. R., Howard, S. V., Mantel, N., McPherson, K., Peto, J., & Smith, P. G. (1977) · British Journal of Cancer · doi:10.1038/bjc.1977.1 · Cited by 8,285
The American Urological Association Symptom Index for Benign Prostatic Hyperplasia
Barry, M. J., Fowler, F. J., O’Leary, M. P., Bruskewitz, R. C., Holtgrewe, H. L., Mebust, W. K., Cockett, A. T. K., & The Measurement Committee of the American Urological Association (1992) · Journal of Urology · doi:10.1016/s0022-5347(17)36966-5 · Cited by 3,436
Roach, M., Hanks, G., Thames, H., Schellhammer, P., Shipley, W. U., Sokol, G. H., & Sandler, H. (2006) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2006.04.029 · Cited by 2,749
A note on quantifying follow-up in studies of failure time
Schemper, M., & Smith, T. L. (1996) · Controlled Clinical Trials · doi:10.1016/0197-2456(96)00075-x · Cited by 2,575
Partin, A. W. (1997) · JAMA · doi:10.1001/jama.277.18.1445 · Cited by 1,794
Modelling Survival Data in Medical Research
Collett, D. (1994) · Springer eBooks · doi:10.1007/978-1-4899-3115-3 · Cited by 1,065
Zelefsky, M., Leibel, S., Gaudin, P., Kutcher, G., Fleshner, N., Venkatramen, E. S., Reuter, V., Fair, W., Ling, C. C., & Fuks, Z. (1998) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(98)00091-1 · Cited by 924
Roach, M., DeSilvio, M., Lawton, C., Uhl, V., Machtay, M., Seider, M. J., Rotman, M., Jones, C., Asbell, S. O., Valicenti, R. K., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.05.004 · Cited by 637
Pollack, A., Zagars, G. K., Smith, L. G., Lee, J. J., von Eschenbach, A. C., Antolak, J. A., Starkschall, G., & Rosen, I. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.23.3904 · Cited by 521
Roach, M., Marquez, C., Yuo, H.-S., Narayan, P., Coleman, L., Nseyo, U. O., Navvab, Z., & Carroll, P. R. (1994) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/0360-3016(94)90138-4 · Cited by 461
A brief male sexual function inventory for urology
O'Leary, M. P., Fowler, F. J., Lenderking, W. R., Barber, B., Sagnier, P. P., Guess, H. A., & Barry, M. J. (1995) · Urology · doi:10.1016/s0090-4295(99)80304-5 · Cited by 452
Osoba, D., Bezjak, A., Brundage, M., Zee, B., Tu, D., & Pater, J. (2005) · European Journal of Cancer · doi:10.1016/j.ejca.2004.10.017 · Cited by 288
Dose response in prostate cancer with 8–12 years’ follow-up
Hanks, G. E., Hanlon, A. L., Epstein, B. E., et al. (2002) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(02)02954-1 · Cited by 194
Montazeri, A., Harirchi, I., Vahdani, M., Khaleghi, F., Jarvandi, S., Ebrahimi, M., & Haji-Mahmoodi, M. (1999) · Supportive Care in Cancer · doi:10.1007/s005200050300 · Cited by 176
Valicenti, R. K., Lu, J., Pilepich, M. V., Asbell, S. O., & Grignon, D. J. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.14.2740 · Cited by 146
Modelling Survival Data in Medical Research. By D. Collett (Chapman & Hall, 1994) £19.99
Macdonald, A. S. (1995) · British Actuarial Journal · doi:10.1017/s1357321700001173 · Cited by 122
Shih, H. A., Harisinghani, M. G., Zietman, A. L., Wolfgang, J. A., Saksena, M. A., & Weissleder, R. (2005) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2005.07.952 · Cited by 109
A comparison of sample size methods for the logrank statistic
Lakatos, E., & Lan, K. K. G. (1992) · Statistics in Medicine · doi:10.1002/sim.4780110205 · Cited by 100
Vargas, C. E., Galalae, R., Demanes, J., Harsolia, A., Meldolesi, E., Nuernberg, N., Schour, L., & Martinez, A. A. (2005) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2005.04.026 · Cited by 47
Pollack, A. S. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.01.129 · Cited by 11
Cited by
Heidenreich, A., Bastian, P. J., Bellmunt, J., Bolla, M., Joniau, S., van der Kwast, T., Mason, M., Matveev, V., Wiegel, T., Zattoni, F., et al. (2014) · European Urology · doi:10.1016/j.eururo.2013.09.046 · Cited by 1,936
Heidenreich, A., Bellmunt, J., Bolla, M., Joniau, S., Mason, M., Matveev, V., Mottet, N., Schmid, H.-P., van der Kwast, T., Wiegel, T., et al. (2011) · European Urology · doi:10.1016/j.eururo.2010.10.039 · Cited by 1,492
Carrie, C., Hasbini, A., de Laroche, G., Richaud, P., Guerif, S., Latorzeff, I., Supiot, S., Bosset, M., Lagrange, J.-L., Beckendorf, V., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)00111-x · Cited by 365
Self-citationGolfam, M., Samant, R., Eapen, L., & Malone, S. (2012) · Current Oncology · doi:10.3747/co.19.963 · Cited by 11
Metadata
- Authors
- Pommier, P., Chabaud, S., Lagrange, J. L., Richaud, P., Lesaunier, F., Le Prise, E., Wagner, J. P., Hay, M. H., Beckendorf, V., Suchaud, J. P., du Chatelard, P. M. P., Bernier, V., Voirin, N., Perol, D., & Carrie, C.
- Venue
- Journal of Clinical Oncology
- Published
- 2007-12-01
- Volume
- 25
- Issue
- 34
- Pages
- 5366-5373
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2118792538
- Cited by
- 340
- References
- 25
- FWCI
- 13.54
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.